-
公开(公告)号：US20170305932A1
公开(公告)日：2017-10-26
申请号：US15513357
申请日：2015-10-02
Applicant: UCB Biopharma SPRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07D495/18 , C07D487/18 , C07D491/18 , C07F7/18 , C07D513/18
CPC classification number: C07D519/00 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D471/18 , C07D487/08 , C07D487/18 , C07D491/08 , C07D491/18 , C07D493/18 , C07D495/08 , C07D495/18 , C07D513/18 , C07F7/1804
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US09932343B2
公开(公告)日：2018-04-03
申请号：US15102003
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Mark Daniel Calmiano , Sabine Defays , Veronique Durieu , Michael Deligny , Jag Paul Heer , Victoria Elizabeth Jackson , Jean Keyaerts , Boris Kroeplien , Malcolm Mac Coss , Yogesh Anil Sabnis , Matthew Duncan Selby , Dominique Louis Leon Swinnen , Nathalie Van Houtvin , Zhaoning Zhu , Uwe Heinelt , Volkmar Wehner
IPC: A61K31/415 , A61K31/495 , A61K31/44 , A61K31/425 , C07D403/02 , C07D487/00 , C07D513/00 , C07D491/00 , C07D498/02 , C07D487/04 , A61K31/4188 , C07D471/04 , C07D498/04 , C07D519/00 , C07D513/04
CPC classification number: C07D487/04 , A61K31/4188 , C07D471/04 , C07D498/04 , C07D513/04 , C07D519/00
Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
3.发明申请公开(公告)号：US20160304523A1
公开(公告)日：2016-10-20
申请号：US15102003
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Mark Daniel Calmiano , Sabine Defays , Veronique Durieu , Michael Deligny , Jag Paul Heer , Victoria Elizabeth Jackson , Jean Keyaerts , Boris Kroeplien , Malcolm Mac Coss , Yogesh Anil Sabnis , Matthew Duncan Selby , Dominique Louis Leon Swinnen , Nathalie Van Houtvin , Zhaoning Zhu , Uwe Heinelt , Volkmar Wehner
IPC: C07D487/04 , C07D519/00 , C07D513/04 , C07D471/04 , C07D498/04
CPC classification number: C07D487/04 , A61K31/4188 , C07D471/04 , C07D498/04 , C07D513/04 , C07D519/00
Abstract: A series of tricyclic benzimidazole derivatives, in particular dihydro-1H-imidazo [1,2-a]benzimidazole, dihydro-1H-pyrrolo [1,2-a]benzimidazole, dihydro-1H-pyrazino[1,2-a]benzimidazole, dihydro-1H-[1,4]oxazino[4,3-a]benzimidazole and dihydrothiazolo[3,4-a]benzimidazolem, and analogues thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 一系列三环苯并咪唑衍生物，特别是二氢-1H-咪唑并[1,2-a]苯并咪唑，二氢-1H-吡咯并[1,2-a]苯并咪唑，二氢-1H-吡嗪并[1,2-a]苯并咪唑 ，二氢-1H- [1,4]恶嗪并[4,3-a]苯并咪唑和二氢噻唑并[3,4-a]苯并咪唑及其类似物是人TNFα活性的有效调节剂，因此在治疗和 /或预防各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US20150152065A1
公开(公告)日：2015-06-04
申请号：US14406848
申请日：2013-06-11
Applicant: UCB Biopharma SPRL
Inventor： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley
IPC: C07D235/12 , C07D401/04 , A61K31/4439 , A61K31/454 , C07D405/06 , A61K31/4192 , C07D403/04 , A61K31/4709 , A61K31/4725 , A61K31/444 , C07D401/14 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D491/107 , A61K31/506 , A61K31/4184
CPC classification number: C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107
Abstract: A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US10775385B2
公开(公告)日：2020-09-15
申请号：US15736614
申请日：2015-10-22
Applicant: UCB Biopharma SPRL
Inventor： James Philip O'Connell , John Robert Porter , Alastair Lawson , Boris Kroeplien , Stephen Edward Rapecki , Timothy John Norman , Graham John Warrellow , Tracy Lynn Arakaki , Alex Buntin Burgin , William Ross Pitt , Mark Daniel Calmiano , David Andreas Schubert , Daniel John Lightwood , Rebecca Jayne Wootton
IPC: G01N33/68 , C07K14/525 , C07K14/705 , C07K16/24 , A61P37/00 , C07D401/14 , C07D471/00 , C07D213/72 , C07D235/04 , C07D239/26 , C07D471/04 , A61K47/64 , A61P35/00
Abstract: A new, stable trimeric TNFα structure is disclosed with distorted symmetry which can bind to the TNFR1 receptor to attenuate signalling therefrom, which can be used in the treatment and/or prevention of diseases associated with the soluble TNFα/TNFR1 interaction. Membrane-bound TNFα is not affected in its ability to signal through TNFR2, and thus the new structure of TNFα may be used in therapies which do not significantly raise the risk of infection or malignancy.
-
Patent Agency Ranking
公开(公告)号：US10202405B2
公开(公告)日：2019-02-12
申请号：US15513357
申请日：2015-10-02
Applicant: UCB Biopharma SPRL , Sanofi
Inventor： Teresa De Haro Garcia , Michael Deligny , Jag Paul Heer , Joanna Rachel Quincey , Mengyang Xuan , Zhaoning Zhu , Daniel Christopher Brookings , Mark Daniel Calmiano , Yves Evrard , Martin Clive Hutchings , James Andrew Johnson , Sophie Jadot , Jean Keyaerts , Malcolm Mac Coss , Matthew Duncan Selby , Michael Alan Shaw , Dominique Louis Leon Swinnen , Laurent Schio , Yann Foricher , Bruno Filoche-Romme
IPC: C07D519/00 , C07F7/18 , C07D471/18 , C07D487/18 , C07D493/18 , C07D491/08 , A61K31/4184 , A61K31/506 , A61K31/55 , C07D487/08 , C07D491/18 , C07D495/08 , C07D495/18 , C07D513/18
Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6,7-dihydro-7,14-methanobenzimidazo[1,2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.
-
公开(公告)号：US09550737B2
公开(公告)日：2017-01-24
申请号：US14406848
申请日：2013-06-11
Applicant: UCB Biopharma SPRL
Inventor： Daniel Christopher Brookings , Mark Daniel Calmiano , Ellen Olivia Gallimore , Helen Tracey Horsley , Martin Clive Hutchings , James Andrew Johnson , Boris Kroeplien , Fabien Claude Lecomte , Martin Alexander Lowe , Timothy John Norman , John Robert Porter , Joanna Rachel Quincey , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu , Anne Marie Foley
IPC: C07D401/04 , C07D401/14 , C07D403/04 , C07D491/107 , C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D405/06
CPC classification number: C07D235/12 , A61K31/4184 , A61K31/4192 , A61K31/4439 , A61K31/444 , A61K31/454 , A61K31/4709 , A61K31/4725 , A61K31/506 , A61K31/5377 , A61K31/541 , A61K31/551 , C07D401/04 , C07D401/14 , C07D403/04 , C07D405/06 , C07D491/107
Abstract: A series of benzimidazole derivatives, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
Abstract translation: 因此，作为人TNFα活性的有效调节剂的一系列苯并咪唑衍生物有益于治疗和/或预防各种人类疾病，包括自身免疫和炎性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。
-
公开(公告)号：US10087179B2
公开(公告)日：2018-10-02
申请号：US15101767
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Rikki Peter Alexander , Gareth Neil Brace , Julien Alistair Brown , Mark Daniel Calmiano , Prafulkumar Tulshibhai Chovatia , Michael Deligny , Ellen Olivia Gallimore , Jag Paul Heer , Victoria Elizabeth Jackson , Boris Kroeplien , Malcolm MacCoss , Joanna Rachel Quincey , Yogesh Anil Sabnis , Dominique Louis Léon Swinnen , Zhaoning Zhu , Uwe Heinelt , Volkmar Wehner
IPC: C07D471/04 , C07D519/00 , A61K31/437
Abstract: A series of fused tricyclic imidazole derivatives, in particular dihydro-1H-cyclopenta[4,5]imidazo[1,2-a]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US10004737B2
公开(公告)日：2018-06-26
申请号：US15039092
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Julien Alistair Brown , Mark Daniel Calmiano , Elizabeth Pearl Jones , Boris Kroeplien , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: A61K31/506 , A61K31/437 , A61K31/444 , A61K31/5377 , A61K31/4985 , C07D471/04 , C07D487/04 , C07D519/00 , A61K45/06
Abstract: A series of substituted benzimidazole, imidazo[1,2-α]pyridine and pyrazolo[1,5-α]pyridine derivatives, and analogs thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
公开(公告)号：US20170128445A1
公开(公告)日：2017-05-11
申请号：US15039092
申请日：2014-12-08
Applicant: UCB BIOPHARMA SPRL
Inventor： Julien Alistair Brown , Mark Daniel Calmiano , Elizabeth Pearl Jones , Boris Kroeplien , James Thomas Reuberson , Matthew Duncan Selby , Michael Alan Shaw , Zhaoning Zhu
IPC: A61K31/506 , A61K31/437 , A61K31/444 , C07D487/04 , A61K31/5377 , C07D471/04 , C07D519/00
CPC classification number: A61K31/506 , A61K31/437 , A61K31/444 , A61K31/4985 , A61K31/5377 , A61K45/06 , C07D471/04 , C07D487/04 , C07D519/00 , A61K2300/00
Abstract: A series of substituted benzimidazole, imidazo[1,2-α]pyridine and pyrazolo[1,5-α]pyridine derivatives, and analogues thereof, being potent modulators of human TNFα activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
-
-
-
-
-
-
-
-
-
Search Results
10
records
(took 0.026 seconds)
